{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:58:25Z","timestamp":1764349105000},"reference-count":15,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Efinaconazole is a novel triazole antifungal drug for the topical treatment of onychomycosis, a nail infection caused mainly by dermatophytes. We assessed the potential of efinaconazole to induce resistance in dermatophytes by continuous exposure of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Trichophyton rubrum<\/jats:named-content>\n            strains to efinaconazole\n            <jats:italic>in vitro<\/jats:italic>\n            (12 passages) and in a guinea pig onychomycosis model (8 weeks). There was no evidence of efinaconazole resistance development in the tested strains under the experimental conditions used.\n          <\/jats:p>","DOI":"10.1128\/aac.02703-13","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T07:08:08Z","timestamp":1401260888000},"page":"4920-4922","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Assessment of Dermatophyte Acquired Resistance to Efinaconazole, a Novel Triazole Antifungal"],"prefix":"10.1128","volume":"58","author":[{"given":"Atsushi","family":"Iwata","sequence":"first","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomichi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Katafuchi-Nagashima","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Pillai","sequence":"additional","affiliation":[{"name":"Dow Pharmaceutical Sciences, Valeant Pharmaceuticals N.A. LLC, Petaluma, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074118"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.4.501"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2010.525230"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02056-12"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_3_3_10_2","volume-title":"In vitro and in vivo evaluation of the potential of onychomycosis causative agents to acquire resistance to efinaconazole, abstr M-248","author":"Iwata A","year":"2013","unstructured":"IwataAWatanabeYKumagaiNNagashimaMSugiuraKTatsumiYPillaiR. 2013. In vitro and in vivo evaluation of the potential of onychomycosis causative agents to acquire resistance to efinaconazole, abstr M-248. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 10 to 13 September 2013."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3634-3636.2003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01084-13"},{"key":"e_1_3_3_13_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802227308"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn245"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3797-3801.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02703-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02703-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:55:34Z","timestamp":1645484134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02703-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1128\/AAC.02703-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02703-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"2013-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}